Rosuvastatin for the treatment of dyslipidemia in HIV-infected patients receiving highly active antiretroviral therapy. Preliminary experience;Rosuvastatina para tratamiento de la dislipidemia en pacientes infectados con VIH en tratamiento antirretroviral de gran actividad. Experiencia preliminar

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 26, Issue 6, 2008, Pages 325-329

  Bottaro, Edgardo Gabriel ^a,b,c   Caravello, Óscar ^b   Scapellato, Pablo Gustavo ^b   Stambulian, Marcela ^a   Vidal, Gabriela Inés ^b   Loggia, Verónica ^b   Scapellato, José Luis ^b   Thompson, Flavia ^b   Cassetti, Isabel ^a  

^a Donación F Santojanni ^*  (Argentina)

^b HOSPITAL DURAND   (Argentina)

^c NONE   (Argentina)

Author keywords

Cardiovascular risk; Dyslipidemia; HAART; HIV; Hypercholesterolemia; Rosuvastatin

Indexed keywords

ATORVASTATIN; CYTOCHROME P450; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ROSUVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CHI SQUARE TEST; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; DRUG EFFICACY; DRUG WITHDRAWAL; DYSLIPIDEMIA; FEMALE; GASTROINTESTINAL SYMPTOM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTRIGLYCERIDEMIA; MAJOR CLINICAL STUDY; MALE; MYOSITIS; RETROSPECTIVE STUDY; SINGLE DRUG DOSE; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 45849136710     PISSN: 0213005X     EISSN: 15781852     Source Type: Journal    
DOI: 10.1157/13123836     Document Type: Article

References (27)

1. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338:853-60.
2. Periard D, Telenti A, Sudre P, Cheseaux JJ, Halfon P, Reymond MJ, et al. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. Circulation. 1999;100:700-5.
3. Vigouroux C, Gharakhanian S, Salhi Y, Nguyen TH, Chevenne D, Capeau J, et al. Diabetes, insulin resistance and dyslipidaemia in lipodystrophic HIV-infected patients on highly active antiretroviral therapy (HAART). Diabetes Metab. 1999;25:225-32.
4. Fichtenbaum CJ, Gerber JG, Rosenkranz SL, Segal Y, Aberg JA, Blaschke T, et al. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers; ACTG Study A5047. AIDS. 2002;16:569-77.
5. Dube MP, Stein JH, Aberg JA, Fichtenbaum CJ, Gerber JG, Tashima KT, et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: Recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis. 2003;37:613-27.
6. Polo R, Galindo JM, Martínez E, Álvarez J, Arévalo JM, Asensi V, et al. Recommendations of the Study Group for Metabolic Alterations/Secretariat for the National AIDS Plan (GEAM/SPNS) on the management of metabolic and morphologic alterations in patients with HIV infection. Enferm Infecc Microbiol Clin. 2006;24:96-117.
7. Hanefeld M. Clinical rationale for rosuvastatin, a potent new HMG-CoA reductase inhibitor. Int J Clin Pract. 2001;55:399-405.
8. Bullano MF, Wertz DA, Yang GW, Kamat S, Borok GM, Gandhi S, et al. Effect of rosuvastatin compared with other statins on lipid levels and National Cholesterol Education Program goal attainment for low-density lipoprotein cholesterol in a usual care setting. Pharmacotherapy. 2006;26:469-78.
9. Fonseca FA, Ruiz A, Cardona-Muñoz EG, Silva JM, Fuenmayor N, Marotti M. The DISCOVERY PENTA study: A Direct Statin comparison of LDL-C value - An evaluation of rosuvastatin therapy compared with atorvastatin. Curr Med Res Opin. 2005;21:1307-15.
10. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Educative Program (NCEP) Expert Panel on Detection Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panell III). JAMA. 2001;2486-97.
11. Eblen-Zajjur A, Eblen-Zajjur M. Cálculo de la concentración de colesterol de la lipoproteína de baja densidad: Análisis de regresión versus fórmula de Friedewald. Rev Med Chile. 2001;129:1263-70.
12. Puavilai W, Laoragpongse D. Is calculated LDL-C by using the new modified Friedewald equation better than the standard Friedewald equation? J Med Assoc Thai. 2004;87:589-93.
13. Blankenhorn, DH, Alaupovic P, Wickham E, Chin HP, Azen SP. Prediction of angiographic change in native human coronary arteries and aortocoronary bypass grafts. Lipid and nonlipid factors. Circulation. 1990;81:470-6.
14. Kurth T, Everett BM, Buring JE, Kase CS, Ridker PM, Gaziano JM. Lipid levels and the risk of ischemic stroke in women. Neurology. 2007;68:556-62.
15. Division of AIDS (DAIDS). Table for grading severity of adult adverse experiences for the HIV Prevention Trials Network. Disponible en: http://rcc.tech-res.com/WebContactsheet_v05.htm
16. Sulkowski MS, Thomas DL, Mehta SH, Chaisson RE, Moore RD. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: Role of hepatitis C and B infections. Hepatology. 2002;35:182-9.
17. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial. Lancet. 2003;361:1149-58.
18. Deedwania PC, Hunninghake DB, Bays HE, Jones PH, Cain VA, Blasetto JW, et al. Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome. Am J Cardiol. 2005;95:360-6.
19. Barry M, Gibbons S, Back D, Mulcahy F. Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations. Clin Pharmacokinet. 1997;32:194-209.
20. Fichtenbaum CJ, Gerber JG. Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection. Clin Pharmacokinet. 2002;41:1195-211.
21. Gerber JG, Rosenkranz SL, Fichtenbaum CJ, Vega JM, Yang A, Alston BL, et al. Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: Results of AIDS Clinical Trials Group 5108 Study. J Acquir Immune Defic Syndr. 2005;39:307-12.
22. Visnegarwala F, Maldonado M, Sajja P, Minihan JL, Rodríguez- Barradas MC, Ong O, et al. Lipid lowering effects of statins and fibrates in the management of HIV dyslipidemias associated with antiretroviral therapy in HIV clinical practice. J Infect. 2004;49:283-90.
23. Mallon PW, Miller J, Kovacic JC, Kent Hughes J, Norris R, Samaras K, et al. Effect of pravastatin on body composition and markers of cardiovascular disease in HIV-infected men - A randomized, placebo-controlled study. AIDS. 2006;20:1003-10.
24. Shepherd J, Vidt DG, Miller E, Harris S, Blasetto J. Safety of rosuvastatin: Update on 16,876 rosuvastatin-treated patients in a Multinational Clinical Trial Program. Cardiology. 2007;107:433-43.
25. Calza L, Colangeli V, Manfredi R, Legnani G, Tampellini L, Pocaterra D, et al. Rosuvastatin for the treatment of hyperlipidaemia in HIV-infected patients receiving protease inhibitors: A pilot sudy. AIDS. 2005;19:1103-4 (letter).
26. Van Der Lee M, Vogel M, Schippers E, Rockstroh J, Fätkenheuer G, Wyen C, et al. Pharmacokinetics and Pharmacodynamics of Combined Use of Lopinavir/ritonavir and Rosuvastatin in HIV-infected Patients. 13th Conference on Retroviruses and Opportunistic Infections;2006 February 5-6, 2006. Denver Colorado, USA. (Abstract 588.)
27. Moyle GJ, Lloyd M, Reynolds B, Baldwin C, Mandalia S, Gazzard BG. Dietary advice with or without pravastatin for the managemente of hypercholesterolaemia associated with protease inhibitor therapy. AIDS. 2001;15:1503-8.